Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649

被引：0
|
作者：
Moehler, M. [1 ]
Elimova, E. [2 ]
Blum, S., I [3 ]
Xiao, H. [3 ]
Davenport, E. [4 ]
Wang, J. [4 ]
Hunter, S. [4 ]
Li, M. [3 ]
Kondo, K. [3 ]
Wyrwicz, L. [5 ]
机构：
[1] Johannes Gutenberg Univ Clin, Mainz, Germany
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] RTI Hlth Solut, Res Triangle Pk, NC USA
[5] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep150
引用
下载
收藏
页码：214 / 215
页数：2
相关论文
共 50 条
  • [41] Economic evaluation of trifluridine/tipiracil (TT) versus nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastro-esophageal junction cancer (GEJC) in Canada
    Virik, Kiran
    Wilson, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [42] Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
    Janjigian, Yelena Yuriy
    Adenis, Antoine
    Aucoin, Jean-Sebastien
    Barone, Carlo
    Boku, Narikazu
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey
    Hall, J. P.
    Khela, K.
    Moon, R.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S918 - S918
  • [44] Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.
    Mansoor, Wasat
    Kulkarni, Amit S.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Sunpaweravong, Patrapim
    Alsina, Maria
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Norquist, Josephine
    Shah, Sukrut
    Shen Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [46] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
    Hall, J.
    Khela, K.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    VALUE IN HEALTH, 2020, 23 : S485 - S485
  • [47] Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).
    Lorusso, Domenica
    Colombo, Nicoletta
    Herraez, Antonio Casado
    Santin, Alessandro
    Colomba, Emeline
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Baron-Hay, Sally E.
    Ray-Coquard, Isabelle Laure
    Shapira-Frommer, Ronnie
    Kim, Yong Man
    McCormack, Mary
    Bird, Steven
    Prabhu, Vimalanand S.
    Nguyen, Allison Martin
    Zhao, Qi
    Dutta, Lea
    Makker, Vicky
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [49] CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.
    Moehler, Markus H.
    Janjigian, Yelena Yuriy
    Adenis, Antoine
    Aucoin, Jean-Sebastien
    Boku, Narikazu
    Chau, Ian
    Cleary, James M.
    Feeney, Kynan
    Franke, Fabio A.
    Mendez, Guillermo Ariel
    Schenker, Michael
    Li, Mingshun
    Hitre, Erika
    Couture, Felix
    Karamouzis, Michalis
    Etienne, Pierre-Luc
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) plus ipilimumab (ipi) or nivo plus chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.
    Moehler, Markus H.
    Janjigian, Yelena Yuriy
    Adenis, Antoine
    Aucoin, Jean-Sebastien
    Boku, Narikazu
    Chau, Ian
    Cleary, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345